期刊文献+

Caspase-7、Caspase-3、Survivin与乳腺癌新辅助化疗的关系 被引量:3

Correlation between expression of Caspase-7,Caspase-3,Survivin and neoadjuvant chemotherapy in breast neoplasm
暂未订购
导出
摘要 目的探讨新辅助化疗疗效与Caspase-7、Caspase-3、Survivin的关系。方法用免疫组织化学法检测46例乳腺癌新辅助化疗前后石蜡包埋福尔马林固定标本Caspase-7、Caspase-3、Survivin的表达变化。结果新辅助化疗有效率为80.43%。Caspase-7新辅助化疗前后阳性率分别为67.39%、86.96%,P<0.05;Caspase-3分别为63.04%、84.78%,P<0.05;Survivin分别为71.74%、47.83%,P<0.05。化疗前Caspase-7与Caspase-3阳性者化疗疗效好于阴性者(P均<0.05)。结论Caspase-7、Caspase-3、Survivin的表达变化与新辅助化疗疗效密切相关。 [ Objective ] To study the relationship between neoadjuvant chemotherapy and Caspase-7, Caspase-3, Survivin gene. [ Methods ] Expression of Caspase-7, Caspase-3 and Survivin were examined by immunohistoehemistry in 46 breast neoplasm patients treated with neoadjuvant chemotherapy. [ Results] The overall response rate of neoadjuvant chemotherapy was 80.43%. The expression of Caspase-3 and Caspase-7 were significantly increased after chemotherapy (P 〈 0.05 ) , while that of survivin was decreased (P 〈 0.05 ). Compared with Caspase-7 or Caspase-3 negative cases, positive cases were sensitive to chemotherapy ( P 〈 0.05 ). [ Conclusions] Up-regnlatod Caspase-3, Caspase-7 and down-regnlatod Survivin correlate with the response rate of neoadjuvant chemotherapy.
出处 《山东医药》 CAS 北大核心 2007年第27期12-13,共2页 Shandong Medical Journal
关键词 乳腺肿瘤 新辅助化疗 CASPASE-7 CASPASE-3 SURVIVIN breast neoplasm neoadjuvant chemotherapy Caspase-7 Caspase-3 Survivin
  • 相关文献

参考文献5

  • 1Kaufmann M, Hortobagyi GN, Goldhirsch A, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update [J]. J Clin Oncol, 2006,24(12) :1940-1949.
  • 2Zoli W, Ulivi P, Tesei A, et al. Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines [J]. Breast Cancer Res, 2005,7(5) :681-689.
  • 3Tham YL, Gomez LF, Mohsin S, et al. Clinical response to neoadjurant docetaxel predicts improved outcome in patients with large locally advanced breast cancers [J]. Breast Cancer Res Treat, 2005,94 ( 3 ) :279-284.
  • 4Vegran F, Boidot R, Oudin C, et al. Distinct expression of survivin splice variants in breast carcinomas [J]. Int J Oncol, 2005,27(4) : 1151-1157.
  • 5赵晓利,李力,郭建新,徐德斌,胡珊,陈竹钦.顺铂诱导survivin表达改变与宫颈癌细胞化疗敏感性的关系[J].第三军医大学学报,2005,27(10):1023-1025. 被引量:6

二级参考文献9

  • 1Ambrosini G,Adida C,Altieri D C,et al.A novel anti-apoptosis gene,survivin,expressed in cancer and lymphoma[J].Nat Med,1997,3(8):917-921.
  • 2Adida C,Crotty P L,McGrath J,et al.Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation[J].Am J Pathol,1998,152(1):43-49.
  • 3Yu J,Leung W K,Ebert M P,et al.Increased expression of survivin in gastric cancer patients and in first degree relatives[J].Br J Cancer,2002,87(1):91-97.
  • 4Grabowski P,Kuhnel T,Muhr-Wilkenshoff F,et al.Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma[J].Br J Cancer,2003,88(1):115-119.
  • 5Tamm I,Wang Y,Sausville E,et al.IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95),Bax,caspases,and anticancer drugs[J].Cancer Res,1998,58(23):5315-5320.
  • 6Kajiwara Y,Yamasaki F,Hama S,et al.Expression of survivin in astrocytic tumors:correlation with malignant grade and prognosis[J].Cancer,2003,97(4):1077-1083.
  • 7Beardsmore D M,Verbeke C S,Davies C L,et al.Apoptotic and proliferative indexes in esophageal cancer:predictors of response to neoadjuvant therapy[J].J Gastrointest Surg,2003,7(1):77-86.
  • 8Ikeguchi M,Liu J,Kaibara N,et al.Expression of survivin mRNA and protein in gastric cancer cell line (MKN-45) during cisplatin treatment[J].Apoptosis,2002,7(1):23-29.
  • 9赵晓利,李力.宫颈癌治疗模式进展[J].国外医学(肿瘤学分册),2004,31(5):380-383. 被引量:19

共引文献5

同被引文献33

  • 1中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2011版)[J].中国癌症杂志,2011,21(5):367-417. 被引量:281
  • 2Bonadonna G.Evolving concepts in the systemic adjuvant treatment ofbreast cancer[J].Cancer Res,1992,52(8):2127-2137.
  • 3Gwak G,Kim JY,Park K,et al.Comparison of Doxorubicin Plus Doc-etaxel Neoadjuvant Chemotherapy with Doxorubicin Plus Vinorelbine inPrimary Breast Cancer[J].J Breast Cancer,2011,14(2):129-134.
  • 4Kaufmann M,Minckwitz G,Bear HD,et a1.Recommendations from aninternational expert panel on the use of neoadjuvant(primary)systemictreatment of operable breast cancer:new perspectives 2006[J].AnnOncol,2007,18(12):1927-1934.
  • 5Kong X,Moran MS,Zhang N,et al.Meta-analysis confirms achievingpathological complete response after neoadjuvant chemotherapy predictsfavourable prognosis for breast cancer patients[J].Eur J Cancer,2011,47(14):2084-2090.
  • 6Bear HD,Anderson S,Brown A,et al.The effect on tumor response ofadding sequential preoperative docetaxel to preoperative doxorubicinand cyclophosphamide:preliminary results from National Surgical Adju-vant Breast and Bowel Project Protocol B-27[J].J Clin Oncol,2003,21(22):4165-4174.
  • 7Yerushalmi R,Woods R,Ravdin PM,et al.Ki67 in breast cancer:prog-nostic and predictive potential[J].Lancet Oncol,2010,11(2):174-183.
  • 8Caudle AS,Gonzalez-Angulo AM,Hunt KK,et al.Predictors of tumorprogression during neoadjuvant chemotherapy in breast cancer[J].J ClinOncol,2010,28(11):1821-1828.
  • 9Gerdes J,Schwab U,Lemke H,et al.Production of a mouse monoclonalantibody reactive with a human nuclear antigen associated with cell pro-liferation[J].Int J Cancer,1983,31(1):13-20.
  • 10Végran F,Boidot R,Oudin C,et al.Overexpression of caspase-3ssplice variant in locally advanced breast carcinoma is associated withpoor response to neoadjuvant chemotherapy[J].Clin Cancer Res,2006,12(19):5794-5800.

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部